Black Diamond Therapeutics, Inc. (BDTX)

Current Report Filed: 2026-05-07

Black Diamond Therapeutics announced Q1 2026 financial results on May 7, 2026, providing investors with updated operational and financial performance metrics for the three-month period ended March 31, 2026.
The filing is relatively minimal in disclosure detail, with the substantive information relegated to a press release (Exhibit 99.1) that is explicitly not incorporated by reference into the SEC filing, limiting the official record of material information.
The 8-K was signed by Brent Hatzis-Schoch in his capacity as Chief Operating Officer and General Counsel, indicating active leadership management of regulatory obligations.

Quarterly Report Filed: 2026-05-07

The filing contains extensive XBRL tagging for equity compensation and stock-based arrangements, indicating active management of employee incentive plans including stock options, RSUs, and restricted stock throughout Q1 2026.
Notable fair value measurement disclosures across multiple investment categories (money market funds, commercial paper, corporate bonds, US government securities) suggest the company maintains a diversified cash and investment portfolio as of March 31, 2026.
References to a Servier Agreement and At-Market Equity Program in the XBRL data indicate ongoing capital management activities and potential strategic partnerships, with shelf registration statement filed in November 2025 suggesting financial flexibility.
The presence of Revelio Therapeutics Inc. member references in the XBRL tags may indicate subsidiary or acquired entity operations requiring separate tracking, though detailed financial impact cannot be determined from the metadata alone.

Insider Trading Filed: 2026-03-20

The reporting person, Ali Behbahani, acquired 6,919 shares of Black Diamond Therapeutics, Inc. (BDTX) common stock on March 20, 2026 at $2.15 per share, increasing his direct ownership to 93,568 shares.
Behbahani also holds an indirect beneficial ownership of 4,448,757 shares through his role as a manager of NEA 16 GP, LLC, the general partner of NEA Partners 16, L.P., the direct beneficial owner of the securities.
The acquisition of shares by the director suggests confidence in the company's prospects and aligns Behbahani's interests with those of other shareholders.

Insider Trading Filed: 2026-03-20

The reporting person, Prakash Raman, acquired 6,105 shares of the company's common stock at $2.15 per share, increasing their direct ownership to 37,132 shares.
The share acquisition was made in lieu of cash compensation for the reporting person's service as a non-employee director, indicating their continued commitment to the company.
The transaction price of $2.15 per share reflects the closing market price of the company's stock on the previous trading day, suggesting the acquisition was made at fair market value.

Current Report Filed: 2026-03-16

Black Diamond Therapeutics, Inc. announced its financial results for the year and three months ended December 31, 2025, indicating the company's financial performance for the period.
The company did not provide any additional details or context around the financial results in the 8-K filing, limiting investors' ability to assess the underlying business trends and outlook.
Investors should closely monitor any follow-up communications from the company, such as an earnings press release or conference call, to gain more comprehensive insights into Black Diamond Therapeutics' financial and operational performance.

Annual Report Filed: 2026-03-16

Black Diamond Therapeutics, Inc. (BDTX) reported financial results for fiscal year 2025, showing continued growth in revenue and expansion of its drug pipeline through strategic partnerships.
The company's balance sheet remains strong, with a significant cash position and no long-term debt, indicating financial stability and flexibility to fund ongoing research and development activities.
BDTX's stock-based compensation expenses have increased, which could impact profitability and cash flow in the near term, but the company's focus on advancing its pipeline suggests potential for long-term value creation.

Insider Trading Filed: 2026-01-23

Brent Hatzis-Schoch, the Chief Operating Officer and General Counsel of Black Diamond Therapeutics, Inc. (BDTX), was granted a stock option to acquire 250,000 shares of the company's common stock.
The stock option has a grant date of January 21, 2026 and an exercise price of $2.57 per share, with 25% of the shares vesting on January 21, 2027 and the remaining shares vesting in 36 equal monthly installments thereafter.
This option grant suggests that the company is incentivizing and retaining its key executive, which could be positive for the company's long-term growth and stability.

Insider Trading Filed: 2026-01-23

The reporting person, Mark A. Velleca, President and CEO of Black Diamond Therapeutics, Inc., has been granted a stock option to acquire 600,000 shares of the company's common stock at an exercise price of $2.57 per share.
The option vests over a 4-year period, with 25% of the shares vesting on January 21, 2027, and the remaining shares vesting in 36 equal monthly installments thereafter.
This transaction indicates the company's commitment to retaining its leadership and aligning the CEO's interests with those of shareholders through equity-based compensation.

Insider Trading Filed: 2026-01-23

Sergey Yurasov, the Chief Medical Officer of Black Diamond Therapeutics, has been granted a stock option to acquire 250,000 shares of the company's common stock at an exercise price of $2.57 per share.
The option vests over a four-year period, with 25% of the shares vesting on January 21, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to Yurasov's continued service.
This stock option grant represents a vote of confidence in Yurasov's leadership and his ability to contribute to the company's growth and success in the coming years.

Insider Trading Filed: 2026-01-23

Elizabeth Buck, the Chief Scientific Officer of Black Diamond Therapeutics, Inc., has been granted a stock option to acquire 250,000 shares of the company's common stock.
The option vests over a multi-year period, with 25% vesting on January 21, 2027 and the remaining 75% vesting in equal monthly installments thereafter, subject to her continued service.
This stock option grant suggests that the company is incentivizing its senior leadership to drive the company's long-term success and align their interests with those of shareholders.

Insider Trading Filed: 2026-01-23

Erika Jones, the Senior Vice President, Finance and Corporate Controller of Black Diamond Therapeutics, Inc. (BDTX), has been granted a stock option for 200,000 shares of the company's common stock, with 25% vesting on January 21, 2027 and the remainder vesting in 36 equal monthly installments thereafter.
The stock option has an exercise price of $2.57 per share and will expire on January 20, 2036, indicating a long-term incentive for the reporting person to contribute to the company's success.
This insider transaction represents a significant equity award, potentially signaling management's confidence in the company's future prospects and aligning the reporting person's interests with those of shareholders.

Important Information